Standardized SEC financial data for NEOGENOMICS INC — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001077183 · NASDAQ · Services-Testing Laboratories.
Ratios for fiscal year 2025, standardized from SEC filings.
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $444.4M | $484.3M | $509.7M | $591.6M | $660.6M | $727.3M |
| Cost of revenue | $258.6M | $297.3M | $321.8M | $347.0M | $370.5M | $413.0M |
| Gross profit | $185.9M | $187.1M | $187.9M | $244.6M |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $250.6M | $316.8M | $263.2M | $342.5M | $367.0M | $159.6M |
| Inventory | $29.5M | $23.4M | $24.3M | $24.2M | $26.7M | $28.6M |
| Total current assets | $448.7M | $681.5M | $605.3M | $596.8M |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $1.5M | -$26.7M | -$66.0M | -$2.0M | $7.0M | $5.2M |
| Capital expenditures | $29.1M | $64.1M | $30.9M | $28.8M | $41.1M | $27.0M |
| Free cash flow | -$27.6M | -$90.9M | -$96.9M | -$30.7M |
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/NEO/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/NEO/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"| $290.1M |
| $314.3M |
| R&D expense | $8.2M | $21.9M | $30.3M | $27.3M | $31.2M | $37.1M |
| SG&A expense | $143.8M | $221.3M | $243.4M | $243.1M | $259.7M | $273.3M |
| Operating income | -$14.0M | -$118.8M | -$157.6M | -$107.7M | -$92.1M | -$115.9M |
| EBITDA | $11.9M | — | — | — | — | — |
| Interest expense | $7.0M | $8.2M | $7.6M | $6.9M | $3.8M | $1.7M |
| Pretax income | -$14.1M | -$15.1M | -$159.3M | -$97.1M | -$80.7M | -$110.3M |
| Income tax | $18.2M | $6.7M | $15.1M | $9.1M | $1.9M | $2.2M |
| Net income | $4.2M | -$8.3M | -$144.3M | -$88.0M | -$78.7M | -$108.0M |
Standardized from NEOGENOMICS INC's SEC filings — per-share figures split-adjusted. Full history via the API.
| $596.0M |
| $376.3M |
| Property, plant & equipment | $85.9M | $109.5M | $102.5M | $92.0M | $94.1M | $84.8M |
| Goodwill | $211.1M | $527.1M | $522.8M | $522.8M | $522.8M | $524.3M |
| Total assets | $988.3M | $1.87B | $1.74B | $1.68B | $1.64B | $1.36B |
| Total current liabilities | $73.2M | $87.2M | $89.9M | $96.3M | $301.2M | $88.3M |
| Long-term debt | $169.1M | $532.6M | $535.3M | $538.2M | $541.1M | $341.9M |
| Total debt | $171.9M | $533.7M | $535.4M | $538.2M | $741.9M | $341.9M |
| Total liabilities | $294.0M | $761.5M | $742.0M | $739.7M | $735.7M | $523.3M |
| Retained earnings | -$7.2M | -$14.8M | -$159.1M | -$247.1M | -$325.8M | -$433.8M |
| Total equity | $694.3M | $1.11B | $998.0M | $941.5M | $902.3M | $836.6M |
| -$34.0M |
| -$21.8M |
| Investing cash flow | -$159.4M | -$632.4M | $517K | $76.7M | $12.9M | -$12.3M |
| Financing cash flow | $235.6M | $725.3M | $11.8M | $4.6M | $4.6M | -$200.3M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 |